AxoGen, Inc. (NASDAQ:AXGN) Receives $13.80 Average Target Price from Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned an average recommendation of “Buy” from the five research firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $13.80.

Several research firms recently weighed in on AXGN. JMP Securities lifted their price objective on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, August 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 price objective on shares of AxoGen in a research note on Thursday, June 20th. Raymond James assumed coverage on shares of AxoGen in a research note on Monday, July 1st. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, September 25th.

Institutional Investors Weigh In On AxoGen

Institutional investors have recently bought and sold shares of the company. Koss Olinger Consulting LLC acquired a new stake in shares of AxoGen in the 2nd quarter worth $75,000. Lazard Asset Management LLC grew its stake in shares of AxoGen by 30.1% during the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 2,671 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of AxoGen in the 2nd quarter valued at approximately $125,000. BNP Paribas Financial Markets boosted its stake in AxoGen by 8.6% in the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after purchasing an additional 1,651 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock worth $240,000 after purchasing an additional 2,204 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Stock Performance

Shares of NASDAQ:AXGN opened at $14.02 on Friday. The firm’s 50 day simple moving average is $11.93 and its 200-day simple moving average is $8.86. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51. AxoGen has a one year low of $3.45 and a one year high of $15.08. The firm has a market cap of $612.74 million, a PE ratio of -28.04 and a beta of 1.12.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company had revenue of $47.91 million for the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. As a group, equities analysts predict that AxoGen will post -0.33 EPS for the current year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.